Guillain-Barré Syndrome (GBS)

  • 24 Jan 2025

In News:

The Pune Health Department has reported a surge in Guillain-Barré Syndrome (GBS) cases, prompting concern due to its severe neurological impact and association with prior infections or immune responses.

What is Guillain-Barré Syndrome?

  • Nature of Disorder: A rare autoimmune condition where the body’s immune system attacks the peripheral nervous system, affecting voluntary muscle control and sensory signals (e.g., pain, temperature, and touch).
  • Medical Term: Also known as Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP).
  • System Affected: Peripheral nerves, i.e., nerves outside the brain and spinal cord.

Epidemiology:

  • Prevalence: Rare but potentially life-threatening.
  • Age Group Affected: Can occur at any age but is most common between 30 to 50 years.
  • Non-contagious: GBS is not transmitted from person to person.

Causes and Triggers:

  • Exact Cause: Unknown, but usually follows an immune response to:
    • Infections: Campylobacter jejuni (foodborne bacteria), Epstein-Barr Virus (EBV), Cytomegalovirus (CMV), respiratory or urinary tract infections.
    • Vaccinations: Rarely observed post-immunisation.
    • Surgery or trauma: Can act as physical stressors that trigger the syndrome.

Symptoms:

  • Initial Signs: Tingling and weakness starting in the legs, progressing upwards.
  • Progression:
    • Weakness in arms, facial muscles.
    • Difficulty walking or balancing.
    • In severe cases, respiratory paralysis, requiring ventilator support.
  • Onset: Can escalate within hours, days, or weeks.
  • Range: Varies from mild muscle weakness to complete paralysis.

Impact:

  • Neurological Disruption: Affects communication between the brain and muscles.
  • Temporary but Debilitating: Most patients recover over weeks to months, though rehabilitation may be prolonged.
  • Critical Care: May require intensive medical and respiratory support in acute stages.

Diagnosis & Treatment:

  • No definitive cure, but early intervention improves outcomes.
  • Main Treatments:
  • Intravenous Immunoglobulin (IVIG):
    • Contains healthy antibodies from donated blood.
    • Helps suppress the immune attack on nerves.
  • Plasmapheresis (Plasma Exchange): Filters harmful antibodies from the blood.
  • Supportive Therapy:
    • Mechanical ventilation in case of respiratory failure.
    • Physiotherapy for muscle recovery and mobility.